ClinicalTrials.gg
CompletedNCT00345748Updated Apr 25, 2011

A Study of Abatacept in Japanese Patients With Active Rheumatoid Arthritis While Receiving Methotrexate

A Phase 2 interventional study of Abatacept and Placebo in Rheumatoid Arthritis, sponsored by Bristol-Myers Squibb. Completed at 38 sites in Japan. Open to participants aged 20 Years and older. Per ClinicalTrials.gov, last updated 2011-04-25.

Sponsored by Bristol-Myers Squibb · Phase 2, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
194
Allocation
Randomized
Ages
20 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-16

Among 63 studies testing abatacept in Arthritis, Rheumatoid — 3 open to participants now, 4 under way, 3 of them phase 3. Abatacept · Arthritis, Rheumatoid.

Enrollment
25th of 63
194 · median 119
Started
2006
with 2 others
Phase 2
9 of 63
1 open now
Registered
13th of 63
by date
Lead sponsor
33 of 63
Bristol-Myers Squibb

Among the 63 studies testing abatacept in Arthritis, Rheumatoid, this one is the 25th largest by enrollment, is one of 3 that started in 2006, is one of 9 in phase 2, and was the 13th registered.

Arthritis, Rheumatoid

3,335 studies on the registry are indexed under Arthritis, Rheumatoid; 444 are open to participants now.

Browse Arthritis, Rheumatoid studies →

Open to participants now

3 of the 63 studies testing abatacept in Arthritis, Rheumatoid are open now, in 3 countries. Recruiting first, the newest first:

By country, each count listing its studies:

All 3 open studies →

About abatacept

Abatacept: first FDA approval 2005 (ORENCIA), first EMA approval 2007. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 293 Arthritis, Rheumatoid studies recruiting now, 150 (51%) set no upper age limit and 109 (37%) stop at 75 or younger; 15 take children under 18; 36 take healthy volunteers.

This study: 20 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 63 studies testing abatacept in Arthritis, Rheumatoid, or all of them as a file.
02

Study summary

The purpose of this study is to demonstrate that Abatacept combined with Methotrexate will demonstrate a dose response efficacy in Japanese subjects with active Rheumatoid Arthritis similar to the dose response efficacy previously observed in the International clinical trials.

03

Conditions studied

  • Rheumatoid Arthritis
04

Who can participate

Ages eligible
20 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • patients with active Rheumatoid Arthritis while on methotrexate having 12 tender and 10 swollen joints at randomization

Exclusion criteria

Exclusion Criteria:

  • no current infection or other evolutive or uncontrolled disease
05

Study design

Phase
Phase 2
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Double (Participant, Investigator)
Enrollment
194 participants (actual)

Study arms

  • Active comparator
    Abatacept 2 mg/kg

    Drug: Abatacept

  • Active comparator
    Abatacept 10 mg/kg

    Drug: Abatacept

  • Placebo comparator
    Placebo

    Drug: Placebo

Interventions

  • Injection, IV Infusion, Day 1, 15, 29 and every 28 days for 24 weeks

    Also known as: Orencia

  • DrugPlacebo

    Injectio, IV Infusion, Day 1, 15, 29 and every 28 days for 24 weeks

06

What researchers measure

Primary outcomes

  1. Efficacy will be evaluated using the American College of Rheumatology response rate or ACR 20. This means the respective proportion of patients reaching an improvement of at least 20% of the ACR composite index from baseline.

    Time frame: at 6 months

Secondary outcomes

  1. ACR 50 and ACR 70 will be assessed as respectively 50 and 70% improvement of the ACR composite index, quality of life by using SF36 questionnaire, Population Pharmacokinetics, Biomarkers, Immunogenicity

    Time frame: at 6 months

  2. Safety (Severity of adverse events, causal relationship to the study drug, outcome, action taken with respect to the investigational product, treatment required)

    Time frame: at 6 months

07

Study locations

38 sites
  • Local Institution
    Nagoya-Shi, Aichi 460-0001, Japan
  • Local Institution
    Nagoya, Aichi 466-8550, Japan
  • Local Institution
    Goshogawara-Shi, Aomori 037-0053, Japan
  • Local Institution
    Chiba-Shi, Chiba, Japan
  • Local Institution
    Fukui-Shi, Fukui 910-0041, Japan
  • Local Institution
    Fukui-Shi, Fukui 910-0067, Japan
  • Local Institution
    Fukuoka-Shi, Fukuoka 810-0065, Japan
  • Local Institution
    Fukuoka-Shi, Fukuoka 812-0025, Japan
  • Local Institution
    Kitakyushu-Shi, Fukuoka 807-8555, Japan
  • Local Institution
    Higashi-Hiroshima-Shi, Hiroshima 739-0002, Japan
  • Local Institution
    Sapporo City, Hokkaido 060-8648, Japan
  • Local Institution
    Sapporo-City, Hokkaido 060-0001, Japan
  • Local Institution
    Sapporo-City, Hokkaido 060-8604, Japan
  • Local Institution
    Kanzaki-Gun, Hyogo 679-2414, Japan
  • Local Institution
    Kato-Gun, Hyogo 673-1462, Japan
  • Local Institution
    Hitachi-Shi, Ibaraki 316-0035, Japan
  • Local Institution
    Tsukuba-Shi, Ibaraki 305-0005, Japan
  • Local Institution
    Sagamihara-Shi, Kanagawa 228-8522, Japan
  • Local Institution
    Sendai-Shi, Miyagi 981-0911, Japan
  • Local Institution
    Sendai-Shi, Miyagi 982-0032, Japan
  • Local Institution
    Sendai, Miyagi, Japan
  • Local Institution
    Nagano-Shi, Nagano 380-8582, Japan
  • Local Institution
    Tsukubo-Gun, Okayama 701-0304, Japan
  • Local Institution
    Kawachinagano-Shi, Osaka 86-0008, Japan
  • Local Institution
    Ureshino-Shi, Saga 843-0301, Japan
  • Local Institution
    Iruma-Gun, Saitama 350-0495, Japan
  • Local Institution
    Kawagoe-Shi, Saitama 350-8550, Japan
  • Local Institution
    Kitamoto-Shi, Saitama 364-0026, Japan
  • Local Institution
    Hamamatsu-Shi, Shizuoka 430-0906, Japan
  • Local Institution
    Kawachigun, Tochigi 329-1104, Japan
  • Local Institution
    Arakawa-Ku, Tokyo 116-0011, Japan
  • Local Institution
    Bunkyo-Ku, Tokyo 113-0022, Japan
  • Local Institution
    Bunkyo-Ku, Tokyo 113-8519, Japan
  • Local Institution
    Setagaya-Ku, Tokyo 155-0032, Japan
  • Local Institution
    Shinjuku-Ku, Tokyo 162-0054, Japan
  • Local Institution
    Takaoka-Shi, Toyama 933-8525, Japan
  • Local Institution
    Chiba-Shi, 260-0801, Japan
  • Local Institution
    Tochigi, 329-0498, Japan
08

Timeline

Tracking since Sep 25, 2026
Not marked actual or estimatedDates not marked actual or estimated

The record gives a start of Jun 2006, a primary completion of Nov 2007 and a completion of Nov 2007. It does not say whether these dates are actual or estimated.

How these figures are worked out, and which studies are left out of them.

Registered
Jun 23, 2006
First posted
Jun 28, 2006
Start
Jun 2006
Primary completionActual
Nov 2007
CompletionActual
Nov 2007
Results delay requested
Apr 11, 2011
Last update
Apr 25, 2011
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Apr 25, 2011, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
09

Registry details

Key details

Study ID
NCT00345748
First posted
Jun 28, 2006
Start date
Jun 2006
Primary completion
Nov 2007
Completion
Nov 2007
Last update
Apr 25, 2011

Study contacts

Bristol-Myers Squibb
study director · Bristol-Myers Squibb

Oversight

Data monitoring committee
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Apr 2011. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Abatacept

Start the discussion